Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671064 | 0.90 | ITGB3 (0.35) | ITGB3ITGA2BFFAR4 | |
| SCHEMBL14671076 | 0.86 | HSD17B10 (0.32) | TSHRHSD17B10 | |
| SCHEMBL14671072 | 0.85 | OPRL1 (0.34) | OPRL1TSHROPRM1CYP2D6 | |
| SCHEMBL15986915 | 0.81 | ITGB3 (0.38) | ITGB3ITGA2BHSD17B10 | |
| SCHEMBL23968808 | 0.81 | ITGB3 (0.37) | ITGB3ITGA2BTSHRHSD17B10CYP2D6 | |
| SCHEMBL15984371 | 0.77 | SLC7A5 (0.36) | OPRL1 | |
| SCHEMBL824228 | 0.77 | HSD17B10 (0.44) | ITGB3ITGA2BHSD17B10 | |
| SCHEMBL23515863 | 0.77 | TSHR (0.33) | TSHR | |
| SCHEMBL14671067 | 0.76 | KDM4E (0.32) | OPRL1TSHROPRM1 | |
| SCHEMBL22301801 | 0.75 | CYP2D6 (0.40) | TSHRHSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226923-B2 | Spirocyclic molecules as protein kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-01-05 | — | — | US | disclosed |
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2014-08-28 | — | — | US | disclosed |
| WO-2013013308-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | BETA PHARMA CANADA INC. (CA) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243303-A1 | SPIROCYCLIC MOLECULES AS PROTEIN KINASE INHIBITORS | MET, RET, ALK | ITGB3 1665/4885ITGA2B 2254/4885OPRL1 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.